Document is current
Any future updates will be listed below
-
Authors
Schreiber, Stefan https://orcid.org/0000-0003-2254-7771
Waetzig, Georg H.
López-Agudelo, Víctor A.
Geisler, Corinna
Schlicht, Kristina https://orcid.org/0000-0003-0281-5142
Franzenburg, Sina
di Giuseppe, Romina
Pape, Daniel
Bahmer, Thomas
Krawczak, Michael
Kokott, Elisabeth
Penninger, Josef M. https://orcid.org/0000-0002-8194-3777
Harzer, Oliver
Kramer, Jan
von Schrenck, Tammo
Sommer, Felix https://orcid.org/0000-0002-6545-3487
Zacharias, Helena U. https://orcid.org/0000-0003-3633-1330
,
Bokemeyer, Bernd
di Giuseppe, Romina
Gronwald, Wolfram
Harris, Danielle M. M.
Hartmann, Katharina
Hollstein, Tim
Oefner, Peter J.
Plachta-Danielzik, Sandra
Tran, Florian
von Schrenck, Tammo
Millet Pascual-Leone, Belén https://orcid.org/0000-0003-4287-282X
Forslund, Sofia K. https://orcid.org/0000-0003-4285-6993
Heyckendorf, Jan
Aden, Konrad https://orcid.org/0000-0003-3482-7316
Hollweck, Regina
Laudes, Matthias https://orcid.org/0000-0002-7846-955X
Rosenstiel, Philip https://orcid.org/0000-0002-9692-8828
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EXC 2167: CD-1, CD-2, TI-1, EXC 2167, EXC 2167: RTF-VI, EXC 2167, miTARGET (RU5042), SO1141/10-1, SFB1470, SFB1449, miTARGET (RU5042), EXC 2167: CD-1, CD-2, TI-1, EXC 2167: CD-2, RTF-VI, TI-1)
Bundesministerium für Bildung und Forschung (e:Med Juniorverbund “Try-IBD” 01ZX1915A and 01ZX2215, e:Med Network iTREAT 01ZX2202A, e:Med CKDNapp 01ZX1912A, e:Med Juniorverbund “Try-IBD” 01ZX1915A and 01ZX2215, e:Med Network iTREAT 01ZX2202A, e:Med Juniorverbund “Try-IBD” 01ZX1915A and 01ZX2215, e:Med Network iTREAT 01ZX2202A)
Christian-Albrechts-Universität zu Kiel (K126408)
Deutsches Zentrum für Herz-Kreislaufforschung
See funding for individual authors.
- License Information
-
More Information
Article History
Received: 21 May 2024
Accepted: 26 March 2025
First Online: 12 May 2025
Competing interests
: S.S. reports indirect stock ownership in Gerion Biotech as well as consulting and personal fees from AbbVie, Allergosan, Amgen, Arena, BMS, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Galapagos/Gilead, HIKMA, I-Mab, Janssen, Lilly, Morphic, MSD, Mylan, Pfizer, Prometheus, Protagonist, Provention Bio, Sandoz/Hexal, Takeda and Theravance. G.H.W. is employed part-time by the CONARIS Research Institute AG (Kiel, Germany). T.B. reports consulting fees, honoraria or other support from AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, MSD, Novartis, Pfizer and Roche. J.M.P. reports stock ownership in Apeiron Biologics and JLP Health. K.A. reports consulting fees, honoraria or other support from AbbVie, Falk, Galapagos, Janssen, Pfizer and Takeda. M.L. reports a lecture honorarium and travel support by AstraZeneca. P.R. reports stock ownership in Gerion Biotech and consulting fees from Takeda. Additional authors of the COVit-2 Study Group: B.B. reports grants, contracts, consulting fees, honoraria or other support from AbbVie, Arena, BMS, Falk, Ferring, Galapagos, Janssen, MSD and Takeda. D.P. reports meeting support from Advanz Pharma. F.T. reports consulting fees, honoraria or other support from AbbVie, Falk, Janssen, L.E.K. Consulting, Lilly and Sanofi. The remaining authors declare no competing interests.
